The aforementioned studies clearly demonstrate the high expression of PSMA in PBTs (especially in high-grade gliomas) and, consequently, open the door to attractive theragnostic and therapeutic approaches in these tumors, adding new potential weapons to conventional treatments. The gene discussed is FOLH1; the disease is central nervous system cancer.